CF PharmTech executes HKD 0.59 million share buyback; outstanding share count trimmed by 0.01%

Bulletin Express06-09 20:22

CF PharmTech, Inc. (CF PharmTech) reported a new on-market share repurchase on 09 June 2026 under its existing mandate. Key takeaways are as follows:

• Transaction details: 31,000 H-shares were repurchased on the Hong Kong Stock Exchange at prices between HKD 18.52 and HKD 19.14, with a volume-weighted average cost of HKD 18.91 per share. The aggregate consideration amounted to HKD 0.59 million.

• Capital structure impact: The issued share capital (excluding treasury shares) declined from 300.95 million to 300.92 million shares, a reduction of 0.0103%. All repurchased shares are being held as treasury stock, lifting the treasury share balance to 1.30 million. No shares have been cancelled to date. Total issued shares remain at 302.22 million.

• Mandate utilisation: The current repurchase mandate, granted on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases now stand at 1.30 million shares, representing 0.43% of the issued share count on the mandate date.

• Moratorium period: In line with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 09 July 2026.

The board confirms that the repurchase complied with all applicable regulations and there have been no changes to the explanatory statement previously filed with the Exchange.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106329239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106329239","market":"us","top_or_hot":-1,"title":"CF PharmTech executes HKD 0.59 million share buyback; outstanding share count trimmed by 0.01%","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. (CF PharmTech) reported a new on-market share repurchase on 09 June 2026 under its existing mandate. Key takeaways are as follows:</p>\n<p>• Transaction details: 31,000 H-shares were repurchased on the Hong Kong Stock Exchange at prices between HKD 18.52 and HKD 19.14, with a volume-weighted average cost of HKD 18.91 per share. The aggregate consideration amounted to HKD 0.59 million.</p>\n<p>• Capital structure impact: The issued share capital (excluding treasury shares) declined from 300.95 million to 300.92 million shares, a reduction of 0.0103%. All repurchased shares are being held as treasury stock, lifting the treasury share balance to 1.30 million. No shares have been cancelled to date. Total issued shares remain at 302.22 million.</p>\n<p>• Mandate utilisation: The current repurchase mandate, granted on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases now stand at 1.30 million shares, representing 0.43% of the issued share count on the mandate date.</p>\n<p>• Moratorium period: In line with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 09 July 2026.</p>\n<p>The board confirms that the repurchase complied with all applicable regulations and there have been no changes to the explanatory statement previously filed with the Exchange.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech executes HKD 0.59 million share buyback; outstanding share count trimmed by 0.01%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech executes HKD 0.59 million share buyback; outstanding share count trimmed by 0.01%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-09 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. (CF PharmTech) reported a new on-market share repurchase on 09 June 2026 under its existing mandate. Key takeaways are as follows:</p>\n<p>• Transaction details: 31,000 H-shares were repurchased on the Hong Kong Stock Exchange at prices between HKD 18.52 and HKD 19.14, with a volume-weighted average cost of HKD 18.91 per share. The aggregate consideration amounted to HKD 0.59 million.</p>\n<p>• Capital structure impact: The issued share capital (excluding treasury shares) declined from 300.95 million to 300.92 million shares, a reduction of 0.0103%. All repurchased shares are being held as treasury stock, lifting the treasury share balance to 1.30 million. No shares have been cancelled to date. Total issued shares remain at 302.22 million.</p>\n<p>• Mandate utilisation: The current repurchase mandate, granted on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases now stand at 1.30 million shares, representing 0.43% of the issued share count on the mandate date.</p>\n<p>• Moratorium period: In line with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 09 July 2026.</p>\n<p>The board confirms that the repurchase complied with all applicable regulations and there have been no changes to the explanatory statement previously filed with the Exchange.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1106329239","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106329239","pubTimestamp":1781007766,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. (CF PharmTech) reported a new on-market share repurchase on 09 June 2026 under its existing mandate. Key takeaways are as follows: • Transaction details: 31,000 H-shares were...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech执行59万港元股份回购；流通股数量减少0.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. (CF PharmTech) reported a new on-market share repurchase on 09 June 2026 under its existing mandate. Key takeaways are as follows:\n• Transaction details: 31,000 H-shares were repurchased on the Hong Kong Stock Exchange at prices between HKD 18.52 and HKD 19.14, with a volume-weighted average cost of HKD 18.91 per share. The aggregate consideration amounted to HKD 0.59 million.\n• Capital structure impact: The issued share capital (excluding treasury shares) declined from 300.95 million to 300.92 million shares, a reduction of 0.0103%. All repurchased shares are being held as treasury stock, lifting the treasury share balance to 1.30 million. No shares have been cancelled to date. Total issued shares remain at 302.22 million.\n• Mandate utilisation: The current repurchase mandate, granted on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases now stand at 1.30 million shares, representing 0.43% of the issued share count on the mandate date.\n• Moratorium period: In line with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 09 July 2026.\nThe board confirms that the repurchase complied with all applicable regulations and there have been no changes to the explanatory statement previously filed with the Exchange.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106329239","isCrawlerRequest":true}